CytoDyn (CYDY)

Executive Summary

CytoDyn is a clinical-stage biotechnology company developing leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor. The company is primarily focused on solid-tumor oncology indications, with ongoing Phase 1/2 trials evaluating leronlimab in combination with checkpoint inhibitors for various cancers. CytoDyn has faced significant challenges, including regulatory setbacks and financial constraints, but continues to advance its pipeline. Recent efforts have focused on dose optimization and biomarker-driven patient selection to improve outcomes. Despite a volatile history, the company has maintained its commitment to bringing leronlimab to patients with high unmet medical needs.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data for leronlimab in combination with pembrolizumab in solid tumors40% success
• Q3 2026FDA feedback on Phase 3 trial design for leronlimab in metastatic breast cancer60% success
• TBDPartnership or licensing agreement for leronlimab in non-oncology indications (e.g., HIV)25% success